Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership. The agreement pairs UNP's AI-guided macrocyclic design with Novartis' cardiovascular…
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal. The pact extends Novartis's cardiovascular franchise beyond its entrenched…
A nimble Santa Cruz, CA-based biotech has corralled a $45 million Series B to prove whether its decade of R&D in the burgeoning macrocycle space can yield oral…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Unnatural Products (UNP) and Novartis entered a research collaboration and licensing agreement worth up to $100 million in upfront and pre-IND milestones plus up to $1.7 billion in development, regulatory, and commercial milestones, with tiered royalties from mid-single to low double-digits. The collaboration pairs UNP's AI-enhanced macrocycle platform with Novartis' global development capabilities for an undisclosed cardiovascular program. Novartis assumes responsibility for IND-enabling studies, clinical development, manufacturing, and global commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Unnatural Products, Inc. (this deal) | 2026 | $1.8B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2026 deals · Novartis AG deals · Cardiovascular deals